Over the past two decades, 我已经在澳门在线赌城娱乐的所有主要疾病领域发现并开发了新药. 

我的第一个学位是化学工程，在那里我对酶和分子进化产生了兴趣. 在我读博士期间，我研究了在试管中进化具有新功能的蛋白质变体的方法. I then started my career in biotech before moving into R&D leadership and from there clinical development.

在澳门在线赌城娱乐，我首先领导了全球技术部门. 澳门第一赌城在线娱乐研究的创新药物模式最终贡献了澳门第一赌城在线娱乐研究组合的一半以上. 然后我就有机会获得了其中一个药物线索, a dual agonist peptide, into clinical trials and help transform it into a new medicine.

Today, my primary role is to lead a team of drug developers. 澳门第一赌城在线娱乐正在用一系列的模式(小分子)探索人类生物学, peptides, anti-sense nucleotides, siRNAs, proteins, antibodies) across all our indications (cardiovascular disease, heart failure, kidney diseases, liver and metabolic diseases). 澳门第一赌城在线娱乐承担临床前项目，并引导它们进行临床概念验证和III期过渡. As Fellow of Trinity Hall 在剑桥大学，我指导研究生学习蛋白质设计和定向进化主题，这使我与我开始的科学之旅保持密切联系.

每天驱使我的是将科学和创造力结合起来，设计出对患者有影响的新药.

Lutz Jermutus PhD Vice-President, Head of Project Leaders, Early CVRM

2017

MedImmune President’s Award

2015

英国皇家医师学院药学系荣誉院士

2013

Industrial Fellow of Trinity Hall, University of Cambridge

CURRENT ROLE

Vice-President, Head of Project Leaders, Early CVRM

2013-2019

Served as Product Development Team Leader in MedImmune CVRM. 我目前正在研究的肽候选药物具有跨越肝脏和肾脏疾病的潜力. 这是澳门在线赌城娱乐公司在早期研发过程中发现并服用的第一种多肽药物. 我很自豪澳门第一赌城在线娱乐是第一个描述这种双机制化合物的临床前和临床疗效的团队，并能够在《澳门在线赌城娱乐》和《澳门在线赌城娱乐》上发表澳门第一赌城在线娱乐的数据.

2007-2013

在我的职业生涯中，作为MedImmune Research的全球技术主管，我领导了一个R&这是一项扩大澳门第一赌城在线娱乐可以用来创造新药的模式的倡议. 有两个决定让我特别自豪，因为它们都违背了当时公认的智慧:成立一个肽团队, using recombinant and synthetic approaches, resulted in four clinical leads for heart failure, kidney disease and metabolic disease. 澳门第一赌城在线娱乐还成立了一个表型筛选小组:澳门第一赌城在线娱乐首先寻找具有有趣功能的抗体，然后努力了解它们是如何发挥作用的, 在肿瘤学和感染性疾病方面取得了两个临床领先地位.

2003-2007

在读博期间，我完善了一种分子方法来设计新型抗体分子. In my first industry position as Director of Protein Engineering, Cambridge Antibody Technology, 我应用这项技术来帮助创造一种针对IL-13的抗体疗法，IL-13现在是一种被批准的治疗特应性皮炎的药物.

  Featured publications

Technique for protein evolution in the test tube:

Tailoring in vitro evolution for protein affinity or stability. Jermutus L, Honegger A, Schwesinger F, Hanes J, Plückthun A. Proc Natl Acad Sci U S A. 2001;98(1):75-80. doi: 10.1073/pnas.011311398.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC14547/pdf/pq000075.pdf

Discovery of antibodies against IL-13 including tralokinumab:

Probing a protein-protein interaction by in vitro evolution.  Thom G, Cockroft AC, Buchanan AG, Candotti CJ, Cohen EZ, Lowne D, Monk P, Shorrock-Hart CP, Jermutus L, and Minter RR.

http://www.pnas.org/content/103/20/7619

Peptide mimetics of human antibodies:

能够模拟人FcyRI IgG1-Fc功能表位的环状肽鉴定. Bonetto PS, Spadola L, Buchanan AG, Jermutus L, Lund J. 2009; 23(2):575-585. doi: 10.1096/fj.08-117069.

http://faseb.onlinelibrary.wiley.com/doi/full/10.1096/fj.08-117069

Phenotypic selection and discovery of oleclumab:

结合表型和蛋白质组学方法鉴定“三阴性”乳腺癌细胞类型的膜靶点. Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, Karlsson R, Brand E, Lowne D, Elvin J, Flynn M, Kurosawa G, Hollingsworth R, Jermutus L, Minter R.  Mol Cancer. 2013; 13(12):11. doi: 10.1186/1476-4598-12-11.

http://molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-12-11

Alternatives to human antibodies:

Challenges and opportunities for non-antibody scaffold drugs. 刘国强，刘国强，刘国强，刘国强，刘国强. Drug Discov Today. 2015;20(10):1271-83. doi: 10.1016/j.drudis.2015.09.004.

http://www.sciencedirect.com/science/article/pii/S135964461500344X?via%3Dihub

Using proteases instead of antibodies as antagonists of IL-13:

组合筛选确定了新的混杂基质金属蛋白酶(MMP)活性，导致抑制治疗靶点IL-13. Urbach C, Gordon NC, Strickland I, Lowne D, Joberty-Candotti C, May R, Herath A,  Hijnen D, Thijs JL, Bruijnzeel-Koomen CA, Minter RR,  Hollfelder F, Jermutus L. Chem Biol. 2015;22(11):1442-1452. doi: 10.1016/j.chembiol.2015.09.013.

http://www.sciencedirect.com/science/article/pii/S1074552115003816?via%3Dihub

利用定向进化产生一种新的1型糖尿病治疗蛋白

一种cd80偏置的CTLA4-Ig融合蛋白，具有较好的体内低效性, infrequent doses by simultaneous engineering of affinity, selectivity, stability and FcRn binding. Douthwaite D, Moisan J, Privezentzev C, Soskic B, Sabbah S, Cohen S, Collinson A, EliEngland E, Huntington C, Kemp B, Zhuang L, Hudak S, Rees DG, Goldberg D, Barton C, Chang L, Vainshtein I, Liang M, Iciek L, Ambery P, Peakman M, Vaughan TJ, Tree TIM, Sansom DM, Bowen MA, Minter RR and Jermutus L. J Immunol. 2017;198(1) 528-537. doi: http://doi.org/10.4049/jimmunol.1600682. 

http://www.jimmunol.org/content/198/1/528.long

双激动剂肽cotadutide治疗2型糖尿病的首个临床数据:

MEDI0382, a GLP-1 and glucagon receptor dual agonist, 肥胖或超重的2型糖尿病患者:一项随机研究, controlled, double-blind, ascending dose and phase 2a study. Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. Lancet. 2018;391(10140):2607-2618. doi: 10.1016/S0140-6736(18)30726-8.

http://www.sciencedirect.com/science/article/pii/S0140673618307268?via%3Dihub

Mechanism of action of cotadutide:

GLP-1R和GCGR双激动剂共肽通过调节线粒体功能和脂肪生成来解决NASH和肝纤维化. Boland ML, Laker RC, Mather K, Nawrocki A, Oldham S, Boland BB, Lewis H, Conway J, Naylor J, Guionaud S, Feigh M, Veidal SS, Lantier L, McGuinness OP, Grimsby J, Rondinone CM, Jermutus L, Larsen MR, Trevaskis JL, Rhodes CJ. Nat Metab. 2020;2(5):413-431. doi: 10.1038/s42255-020-0209-6.

http://www.nature.com/articles/s42255-020-0209-6

Novel biomarker approach for treatments of Type 1 Diabetes:

滤泡辅助T细胞谱预测1型糖尿病患者对共刺激阻断的反应. Edner NM, Heuts F, Thomas N, Wang CJ, Petersone L, Kenefeck R, Kogimtzis A, Ovcinnikovs V, Ross EM, Ntavli E, Elfaki Y, Eichmann M, Baptista R, Ambery P, Jermutus L, Peakman M, Rosenthal M, Walker LSK. Nat Immunol. 2020;21(10):1244-1255. doi: 10.1038/s41590-020-0744-z.

http://www.nature.com/articles/s41590-020-0744-z

Our people

澳门第一赌城在线娱乐的人民有一个共同的目标:突破科学的界限，提供改变生活的药物.

What science can do

Stories from our people and our partners reveal the passion, 能量和知识使澳门第一赌城在线娱乐能够将科学置于澳门第一赌城在线娱乐所做的一切的核心.

Our company

We are a global, 以科学为主导的澳门第一赌城在线娱乐业务和澳门第一赌城在线娱乐的创新药物被全球数百万患者使用.